Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07571174
PHASE1

A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.

Official title: A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2026-05-14

Completion Date

2029-06

Last Updated

2026-07-17

Healthy Volunteers

No

Interventions

DRUG

LY4256984

Administered IT

Locations (10)

UZ Leuven

Leuven, Belgium

University Hospital - London Health Sciences Centre

London, Canada

McGill University Health Centre

Montreal, Canada

Sunnybrook Research Institute

Toronto, Canada

Universitätsklinikum Schleswig-Holstein

Lübeck, Germany

Universitätsmedizin Rostock

Rostock, Germany

Universitaetsklinikum Ulm

Ulm, Germany

Universitair Medisch Centrum Utrecht

Utrecht, Netherlands

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Spain

Hospital Universitari i Politecnic La Fe

Valencia, Spain